Zobrazeno 1 - 10
of 376
pro vyhledávání: '"Ferrajolo, A."'
Autor:
Crisafulli, Salvatore, Cutroneo, Paola Maria, Verhamme, Katia, Ferrajolo, Carmen, Ficarra, Vincenzo, Sottosanti, Laura, Di Giovanni, Valentina, Spina, Edoardo, Trifirò, Gianluca *
Publikováno v:
In European Urology Focus September 2022 8(5):1424-1432
Autor:
Giuseppe Roberto, Anna Girardi, Francesco Barone-Adesi, Alessandro Pecere, Valentina Ientile, Claudia Bartolini, Roberto Da Cas, Stefania Spila-Alegiani, Carmen Ferrajolo, Paolo Francesconi, Gianluca Trifirò, Elisabetta Poluzzi, Fabio Baccetti, Rosa Gini
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: To verify whether, in patients on metformin (MET) monotherapy for type 2 diabetes (T2D), the add-on of a dipeptidyl peptidase inhibitor (DPP4i) compared to a sulfonylurea (SU) can delay the time to the subsequent treatment intensification
Externí odkaz:
https://doaj.org/article/83e9864b58da41d5af4436722a78a591
Autor:
Mario Gaio, Carmen Ferrajolo, Alessia Zinzi, Consiglia Riccardi, Pasquale Di Filippo, Ludovica Carangelo, Gorizio Pieretti, Francesco Rossi, Giovanni Francesco Nicoletti, Annalisa Capuano
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Introduction: Post-marketing data on the risks associated with direct oral anticoagulants (DOACs) are conflicting and only few studies evaluated a comparison between each different DOAC. Real-world data from pharmacovigilance databases can help to be
Externí odkaz:
https://doaj.org/article/1f0a358ed60d49e6b5c3c5cb0fa2fa7c
Autor:
Giuseppe Roberto, Francesco Barone-Adesi, Francesco Giorgianni, Valeria Pizzimenti, Carmen Ferrajolo, Michele Tari, Claudia Bartolini, Roberto Da Cas, Marina Maggini, Stefania Spila-Alegiani, Paolo Francesconi, Gianluca Trifirò, Elisabetta Poluzzi, Fabio Baccetti, Rosa Gini
Publikováno v:
BMC Endocrine Disorders, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitors (DPP4i) are hypoglycaemic agents licensed for the treatment of type 2 diabetes mellitus (T2DM). Although these drugs possess comparable effi
Externí odkaz:
https://doaj.org/article/04a605883ebf4f0e99f14d8bc520baef
Autor:
Annamaria Mascolo, Cristina Scavone, Concetta Rafaniello, Carmen Ferrajolo, Giorgio Racagni, Liberato Berrino, Giuseppe Paolisso, Francesco Rossi, Annalisa Capuano
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 7 (2020)
Although clinical manifestations of the 2019 novel coronavirus disease pandemic (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), are mainly respiratory symptoms, patients can also develop severe cardiovasc
Externí odkaz:
https://doaj.org/article/0e14bffbf95b4a83834e873cdb4df7e6
Autor:
Janet Sultana, Gianluca Trifirò, Valentina Ientile, Andrea Fontana, Francesco Rossi, Annalisa Capuano, Carmen Ferrajolo
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
PurposeThe aim of the present study was to describe the purchasing patterns of a set of antibiotics used exclusively in an out-patient pediatric setting in Italy using the Farma360 wholesale drug database (IQVIA Solutions Italy), identifying the prop
Externí odkaz:
https://doaj.org/article/4c53b51a377f400f9d0113df13d6562b
Autor:
Rosanna Ruggiero, Federica Fraenza, Cristina Scavone, Gabriella di Mauro, Raffaele Piscitelli, Annamaria Mascolo, Carmen Ferrajolo, Concetta Rafaniello, Liberata Sportiello, Francesco Rossi, Annalisa Capuano
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
BackgroundThe introduction of immune checkpoint inhibitors (ICIs) in clinical practice has brought significant benefits for patients. Seven ICIs are available in Europe: nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab, and ip
Externí odkaz:
https://doaj.org/article/9c79017502904dcc95473c0b9de2f076
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Wharton, Gerold T., Becker, Claudia, Bennett, Dimitri, Burcu, Mehmet, Bushnell, Greta, Ferrajolo, Carmen, Kaplan, Sigal, McMahon, Ann W., Movva, Naimisha, Raman, Sudha R., Scholle, Oliver, Suh, Mina, Sun, Jenny W., Horton, Daniel B.
Publikováno v:
Pharmacoepidemiology & Drug Safety; Jan2024, Vol. 33 Issue 1, p1-13, 13p
Autor:
Ahmadizar F., Luxi N., Raethke M., Schmikli S., Riefolo F., Saraswati P. W., Bucsa C., Osman A., Liddiard M., Maques F. B., Petrelli G., Sonderlichova S., Thurin N. H., Villalobos F., Trifiro G., Sturkenboom M., Moretti U., Bellitto C., Ciccimarra F., Gonella L. A., Arzenton E., Chiamulera C., Lora R., Bellantuono D., Sabaini A., Firenze A., Zodda D., Guidotti F., Zappone M., Alagna B., Cutroneo P. M., Minore C., Costantino C., Vitale F., D'Alessandro G., Morreale I., Marsala L., Farinella D., Bavetta S., Fantini M. P., Reno C., Raschi E., Poluzzi E., Sapigni E., Potenza A. M., Podetti D., Nikitina V., Ricciardelli R., Mogheiseh N., Croce S., Paltrinieri B., Castellani S., Sangiorgi E., Selleri M., Lucchesi S., Catucci G., Savini D., Sacripanti C., Faccioli M., Romio M. S., Rossi L., Radici S., Negri G., Fares L., Ajolfi C., Fadda A., Chiarello A., Pieraccini F., Gavioli B., Palazzi S., Tuccori M., Vannacci A., Bonaiuti R., Ravaldi C., Lombardi N., Crescioli G., Gori F., Tessari R., Zandona E., Zanoni G., Senna G., Crivellaro M. A., Cancian M., Venturini F., Ferri M., Leonardi L., Orzetti S., Caccin E., Baldo P., Capuano A., Rafaniello C., Ferrajolo C., Pagliaro C., Mercaldo M., di Giorgio A., Tari M., Manna S., Farina G., Di Mauro C., De Carlo I., Senesi I., Pileggi C., Palleria C., Gallelli L., De Sarro G., de Sarro C., Verduci C., Papadopoli R., Trabace L., Morgese M., Schiavone S., Tucci P., Bove M., Lapi F., Cricelli C., Racagni G., Tonolo S., Fava G., Giuffrida S., Amato V., Gambera M., Montresor V., Mastropasqua D.
Background and Objectives: The European Medicine Agency extended the use of Comirnaty, Spikevax, and Nuvaxovid in paediatrics; thus, these vaccines require additional real-world safety evidence. Herein, we aimed to monitor the safety of COVID-19 vacc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::c8916ae0b4845b6e45ea4bd7d0d193b1
https://hdl.handle.net/11585/928075
https://hdl.handle.net/11585/928075
